1,3-Diarylpyrazolyl-acylsulfonamides Target HadAB/BC Complex in Mycobacterium tuberculosis.

1,3-Diarylpyrazolyl-acylsulfonamides Target HadAB/BC Complex in Mycobacterium tuberculosis.
复制标题

DOI:
10.1021/acsinfecdis.2c00392
复制
发表时间:
2022-11-11
影响因子:
5.3
通讯作者:
Ghorpade, Sandeep R.
Ghorpade, Sandeep R.
中科院分区:
医学2区
文献类型:
--
作者:
Singh, Vinayak;Grzegorzewicz, Anna E.;Fienberg, Stephen;Muller, Rudolf;Khonde, Lutete Peguy;Sanz, Olalla;Alfonso, Salvatore;Urones, Beatriz;Drewes, Gerard;Bantscheff, Marcus;Ghidelli-Disse, Sonja;Ioerger, Thomas R.;Angala, Bhanupriya;Liu, Jiuyu;Lee, Richard E.;Sacchettini, James C.;Krieger, Inna, V;Jackson, Mary;Chibale, Kelly;Ghorpade, Sandeep R.

文献摘要

参考文献

相似文献

临床验证靶点的替代抑制模式是规避现有临床耐药性的有效策略。在此,我们报告 1,3-二芳基吡唑基-酰基磺酰胺作为 HadAB/BC 的有效抑制剂,HadAB/BC 是一种 3-羟基-ACP 脱水酶复合物,需要反复延长结核分枝杆菌 (Mtb) 中分枝菌酸的分枝菌酸链。化合物 1 抗性 Mtb 突变体中的突变映射到 HadC(Rv0637;K157R),而化学蛋白质组学证实该化合物与 HadA(Rv0635)、HadB(Rv0636)和 HadC 结合。这些化合物有效抑制了 HadAB 和 HadBC 酶的活性,并以浓度依赖性方式影响 Mtb 中分枝菌酸的生物合成。与已知的具有临床意义的3-羟基-ACP脱水酶复合物抑制剂不同,异氧基和硫代乙酰磺酰胺、1,3-二芳基吡唑基-酰基磺酰胺不需要被EthA激活,因此不易受到EthA介导的耐药性。此外,与 Mtb HadAB 复合物中关键化合物的晶体结构揭示了 HadAB 活性位点内独特的结合相互作用,为进一步基于结构的该系列优化提供了有用的工具。
Alternative mode-of-inhibition of clinically validated targets is an effective strategy for circumventing existing clinical drug resistance. Herein, we report 1,3-diarylpyrazolyl-acylsulfonamides as potent inhibitors of HadAB/BC, a 3-hydroxyl-ACP dehydratase complex required to iteratively elongate the meromycolate chain of mycolic acids in Mycobacterium tuberculosis (Mtb). Mutations in compound 1-resistant Mtb mutants mapped to HadC (Rv0637; K157R), while chemoproteomics confirmed the compound’s binding to HadA (Rv0635), HadB (Rv0636), and HadC. The compounds effectively inhibited the HadAB and HadBC enzyme activities and affected mycolic acid biosynthesis in Mtb, in a concentration-dependent manner. Unlike known 3-hydroxyl-ACP dehydratase complex inhibitors of clinical significance, isoxyl and thioacetazone, 1,3-diarylpyrazolyl-acylsulfonamides did not require activation by EthA and thus are not liable to EthA-mediated resistance. Further, the crystal structure of a key compound in a complex with Mtb HadAB revealed unique binding interactions within the active site of HadAB, providing a useful tool for further structure-based optimization of the series.
DOI: 10.1107/s0907444905036693
发表时间: 2006-01-01
影响因子: 2.2
作者:
Evans, P
通讯作者: Evans, P
DOI: 10.1021/acsinfecdis.9b00162
发表时间: 2020-02-14
影响因子: 5.3
作者:
Grzegorzewicz AE;Gee C;Das S;Liu J;Belardinelli JM;Jones V;McNeil MR;Lee RE;Jackson M
通讯作者: Jackson M
DOI: 10.1128/aac.01178-16
发表时间: 2016-11-01
影响因子: 4.9
作者:
Naran, Krupa;Moosa, Atica;Warner, Digby F.
通讯作者: Warner, Digby F.
DOI: 10.1038/nbt.1759
发表时间: 2011-03-01
影响因子: 46.9
作者:
Bantscheff, Marcus;Hopf, Carsten;Drewes, Gerard
通讯作者: Drewes, Gerard
DOI: 10.1107/s0907444904019158
发表时间: 2004-12-01
影响因子: 2.2
作者:
Emsley, P;Cowtan, K
通讯作者: Cowtan, K